imiquimod has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A | 1 |
2 other study(ies) available for imiquimod and pci 32765
| Article | Year |
|---|---|
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Immunity, Innate; Interleukin-17; Interleukin-23; Intraepithelial Lymphocytes; Male; Mice; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Skin | 2020 |
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Topics: Adenine; Animals; BALB 3T3 Cells; Dendritic Cells; Down-Regulation; Imiquimod; Inflammation Mediators; Male; Mice; Neutrophils; Oxidation-Reduction; Oxidative Stress; Peroxidase; Piperidines; Psoriasis; Signal Transduction; Skin | 2020 |